Dissecting Clonal Hematopoiesis in Tissues of Patients with Classic Hodgkin Lymphoma

Alessandra Venanzi, Andrea Marra, Gianluca Schiavoni, Sara G. Milner, Roberto Limongello, Alessia Santi, Valentina Pettirossi, Simona Ultimo, Luisa Tasselli, Alessandra Pucciari, Lorenza Falini, Sofia Sciabolacci, Maria Paola Martelli, Paolo Sportoletti, Stefano Ascaini, Brunangelo Falini, and Enrico Tiacci

ABSTRACT

Clonal hematopoiesis predisposes to hematologic malignancies. However, clonal hematopoiesis is understudied in classic Hodgkin lymphoma (cHL), a mature B-cell neoplasm exhibiting the most abundant microenvironment. We analyzed clonal hematopoiesis in 40 cHL cases by sequencing microdissected tumor cells and matched normal cells from blood and/or lymph nodes. Five patients had blood and/or tissue clonal hematopoiesis. In three of five patients (all failing first-line therapy), clonal hematopoiesis spread through the tissue microenvironment extensively, and featured mutant DNMT3A\textsuperscript{R882H}, KRAS\textsuperscript{G60D}, and DNMT3A\textsuperscript{R882H}+TET2\textsuperscript{Q1274*} in 33%, 92%, and 60% of non-neoplastic cells, respectively. In the latter case, DNMT3A/TET2-mutant clonal hematopoiesis seeded the neoplastic clone, which was infected by the Epstein–Barr virus and showed almost no other somatic mutations exome-wide. In the former case, DNMT3A-mutant clonal hematopoiesis did not originate the neoplastic clone despite dominating the blood and B-cell lineage (∼94% leukocytes; ∼96% mature blood B cells), yet led to NPM1-mutated acute myeloid leukemia 6 years after therapy for cHL. Our results expand to cHL the spectrum of hematologic malignancies associated with clonal hematopoiesis.

SIGNIFICANCE: Clonal hematopoiesis can be present in the cHL tissue, can give rise to the tumor clone, and can spread to large parts of its microenvironment. Even when massive, clonal hematopoiesis does not always give rise to the neoplastic clone of multiple myeloid and lymphoid neoplasms occurring in the same patient.

INTRODUCTION

Clonal hematopoiesis of indeterminate potential (CHIP) is promoted by the age-dependent stochastic occurrence of mutations in driver genes (e.g., DNMT3A and TET2) that confer a fitness advantage to hematopoietic stem/progenitor cells (HSPC; ref. 1). CHIP is frequent in the elderly and predisposes to hematopoietic neoplasms mostly of myeloid or T-cell
Clonal Hematopoiesis in Classic Hodgkin Lymphoma

Sief B.; mean unique coverage depth: 3,425 neoplasms and/or implicated in CHIP (Supplementary Table S2). The same previous experimental pipeline; ref. 15), followed by targeted sequencing of 43 genes recurrently mutated in myeloid normal cells, uncovering several new mutated genes driving lymphoma cell growth and immune evasion (14–17). Clonal hematopoiesis has been detected in HSPCs harvested from 9 of 64 (14%) cHL relapsed patients of unknown age undergoing autologous transplantation (18). However, no data exist on the potential presence of clonal hematopoiesis in the microenvironmental and/or neoplastic components of cHL tissue. Here, we assessed clonal hematopoiesis frequency and tissue distribution in 40 well-characterized cHL cases largely studied at disease onset, and also describe the surprising findings on a young cHL patient with massive CHIP who developed AML following therapy for cHL.

RESULTS

Prevalence of Clonal Hematopoiesis in Patients with cHL

To assess the frequency of clonal hematopoiesis in patients with cHL, we interrogated our previous whole-exome sequencing (WES) data from non-HRS cells of 34 cHL cases, which we used as a matched normal counterpart to call somatic mutations in HRS cells (15). In particular, we reanalyzed WES data focused on a target region of interest represented by 35 genes implicated in CHIP (as defined by Tuval and Shlush; ref. 9 and Table 1 therein). When mutations of such genes were detected in the blood at or above the canonical VAF cutoff of 2% (2), their presence was assessed in nonneoplastic cells microdissected from frozen tissue biopsies (in 8/34 cases; mean unique coverage depth: 149×), focusing on a target region of interest throughout reactive tissue cells (VAF = 3.2%) but not in reactive tissue cells or in HRS cells; the latter had 97 somatic mutations on WES (ref. 15; Fig. 1B; Supplementary Table S2).

Among the 40 patients with cHL studied in total, tissue biopsies were analyzed at onset of lymphoma in 32 cases, at relapse in 7 cases and at both time points in 1 case; for each patient with an available whole-blood sample, the latter was analyzed at the same time point as the tissue biopsy, except in the case studied both at onset and at relapse whereby blood was available only at relapse. Median age was 35 years (range 15–83); 13 patients were >55 and 5 patients >70 years old. Clonal hematopoiesis was detected in the peripheral blood and/or cHL tissue in 5 of 40 cases (12.5%; Table 1). We note that the coverage depth of WES, which was used in the vast majority of our cases, can miss small-sized clonal hematopoiesis, and, therefore, a higher prevalence of clonal hematopoiesis might result upon deeper targeted sequencing. Clonal hematopoiesis was frequent in patients above 70 years (3/5, 60%; cases 3, 4, and 5), whereas only 2 of 35 (5.7%) patients younger than 70 years (cases 1–2) showed clonal hematopoiesis (P = 0.009 by Fisher exact test; Table 1), in line with the known increase of CHIP frequency with age (1–9).

Tissue Distribution of Clonal Hematopoiesis in Patients with cHL

We then dissected the distribution of clonal hematopoiesis through the cHL tissue in each of these five cases. Case 1 was notable for the development of cHL followed by AML and will be described separately in the next section.

Case 2 was a 31-year-old male, who presented with stage I VB at onset and was studied at progression following both doxorubicin hydrochloride, bleomycin, vinblastine sulfate, and dacarbazine (ABVD) and salvage autologous hematopoietic stem cell transplantation (ASCT). He had a mixed cellularity cHL negative for Epstein–Barr virus (EBV) infection, in which a KRASG12D mutation massively expanded throughout reactive tissue cells (VAF = 45.9%) while being absent in HRS cells; conversely, the latter carried 57 somatic protein-changing mutations upon WES (ref. 15; Fig. 1A; Supplementary Table S2).

Case 3 was an 83-year-old male, who had an EBV-positive nodular sclerosis cHL, stage IIA, and died of chemotherapy complications. Targeted sequencing of the onset tissue biopsy documented a likely pathogenic mutation of CBL (G375S; ref. 19) that was present at a relatively low VAF (2.5%) in reactive tissue cells and was absent in HRS cells (Supplementary Fig. S2; Supplementary Table S2).

Case 4 was an 81-year-old female. She had an EBV-negative nodular sclerosis cHL, stage IIA, and remained free from progression 64 months after doxorubicin hydrochloride, vinblastine sulfate, and dacarbazine (AVD) polychemotherapy. She carried a TET2G1487fsI mutation in blood lymphocytes (VAF = 3.2%) but not in reactive tissue cells or in HRS cells; the latter had 97 somatic mutations on WES (ref. 15; Fig. 1B; Supplementary Table S2).

Case 5 was a 73-year-old male, who presented with mixed cellularity cHL stage IIA and was studied at relapse 35 months after six cycles of ABVD. In his tissue biopsy, DNMT3A R882H and TET2Q1274X spread considerably in reactive tissue cells (VAF = 30% and 8.4%, respectively); however, unlike the previous cases (including case 1 also showing DNMT3A R882H-mutant clonal hematopoiesis; see next section), both mutations
Table 1. Prevalence and tissue distribution of clonal hematopoiesis in patients (n = 40) with cHL

<table>
<thead>
<tr>
<th>CH present</th>
<th>Years of age</th>
<th>Pt.#</th>
<th>Time of sampling</th>
<th>Progressed after first-line chemotherapy</th>
<th>Gene mutation</th>
<th>VAF in whole blood</th>
<th>VAF in microdissected Reactive lymphoid cells</th>
<th>VAF in whole tissue section</th>
</tr>
</thead>
<tbody>
<tr>
<td>NO (n = 35)</td>
<td>Median 35 Range 15–75</td>
<td>30</td>
<td>2nd relapse</td>
<td>YES</td>
<td>KRAS G60D</td>
<td>NA</td>
<td>45.9%</td>
<td>ND 22.9%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>83</td>
<td>Onset</td>
<td>Not evaluable</td>
<td>CBL G375S</td>
<td>NA</td>
<td>2.5%</td>
<td>ND NA</td>
</tr>
<tr>
<td></td>
<td></td>
<td>81</td>
<td>Onset</td>
<td>NO</td>
<td>TET2 N1487Ifs84</td>
<td>3.2%</td>
<td>ND</td>
<td>ND NA</td>
</tr>
<tr>
<td>YES (n = 5)</td>
<td>Onset</td>
<td>73</td>
<td>1st relapse</td>
<td>YES</td>
<td>DNMT3A R882H</td>
<td>NA</td>
<td>30%</td>
<td>43% 37.9%</td>
</tr>
<tr>
<td></td>
<td>Onset</td>
<td>45</td>
<td>Onset</td>
<td>YES</td>
<td>DNMT3A R882H</td>
<td>47%</td>
<td>16.4%</td>
<td>ND 12.2%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>NPM1 W288CfsTer12</td>
<td>ND</td>
<td>NA</td>
<td>ND</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>PTPN11 E76K</td>
<td>ND</td>
<td>NA</td>
<td>ND</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>FLT3 ITD</td>
<td>NA</td>
<td>NA</td>
<td>ND</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>FLT3 ITD</td>
<td>NA</td>
<td>NA</td>
<td>ND</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>STAT6 N417Y</td>
<td>NA</td>
<td>ND</td>
<td>36.9%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>STAT6 D419H</td>
<td>NA</td>
<td>35.7%</td>
<td>ND</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>SOCS1 P83Afs*25</td>
<td>NA</td>
<td>98.6%</td>
<td>NA</td>
</tr>
</tbody>
</table>

Abbreviations: CH, clonal hematopoiesis; NA, not available; ND, not detected.

*Mutant/wild-type ratio by fragment length analysis.
Case 2

In this EBV-negative mixed cellularity cHL (case 2), the reactive tissue microenvironment (mostly represented by T cells—not shown) belonged to clonal hematopoiesis almost entirely, as it featured a KRASG60D mutation at a VAF of 45.9%. However, the HRS cell clone developed from a B cell not belonging to clonal hematopoiesis, after acquiring a JAK2 gain and a B2M mutation (genetic lesions typical of cHL), along with 55 additional somatic protein-changing mutations detected by WES in the HRS cell clone (ref. 15; “+55” in the HRS cell nucleus). Myeloid involvement by clonal hematopoiesis is presumptive because we did not have a blood or bone marrow sample from this patient to formally confirm it. HSC, hematopoietic stem cell.

Case 4

In EBV-negative nodular-sclerosis case 4, clonal hematopoiesis (carrying TET2N1487Ifs84), which was detected in whole-blood leukocytes and likely involved the myeloid lineage (only or mainly), did not spread through either the lymphoid HRS cell clone or its reactive tissue microenvironment. Also indicated are mutations of two genes (ITPR3 and GRM7, recurrently targeted in cHL; ref. 15) that were found in HRS cells but not in blood leukocytes of this cHL case, along with an additional 95 somatic protein-changing mutations detected by WES in the HRS cell clone (ref. 15; “+95” in the HRS cell nucleus). (continued on next page)

were carried over in the HRS cell clone, which was infected by EBV and otherwise had only three somatic mutations detected by WES (ref. 15; Fig. 1C; Supplementary Table S2). Retrospective targeted sequencing of whole sections from the formalin-fixed lymph node biopsy at cHL onset of case 5 documented the same DNMT3AR882H and TET2Q1274* mutations at 32% and 22% VAF, respectively (Table 1 and Supplementary Table S2), indicating a consistent association of microenvironmental clonal hematopoiesis with cHL pathogenesis in this patient and confirming the inability of chemotherapy to clear clonal hematopoiesis (9).

Trajectories of Clonal Hematopoiesis in a cHL Patient Sequentially Developing AML

Case 1 was a 45-year-old man diagnosed with nodular sclerosis, stage IVB cHL, negative for EBV (Fig. 2A–C). After failing polychemotherapy with ABVD, he was successfully salvaged with a second-line regimen (ifosfamide, gemcitabine,
In all three cases (1, 2, and 5) with significant clonal hematopoiesis spreading (VAF ≥10%) through the mostly lymphoid microenvironment, the latter was found to be polyclonal upon T-cell receptor gamma gene rearrangement analysis (Supplementary Fig. S3), confirming that the mutations underlying clonal hematopoiesis had occurred in a bone marrow stem or progenitor cell before T-cell lineage commitment. All three patients progressed after first-line chemotherapy, as opposed to 11/35 (31%; Fisher exact test P value 0.043) evaluable patients with absent or nonextensive clonal hematopoiesis in the tumor tissue, who had similar clinical characteristics and received a no less intense first-line therapy (Table 2).

**DISCUSSION**

Here, we provided an initial characterization, largely by WES, of clonal hematopoiesis prevalence and histogenetic distribution in cHL cases mostly studied at disease onset. Clonal hematopoiesis was readily observed in elderly patients with cHL but could be detected also in younger ones, and an even higher prevalence might emerge upon deeper targeted sequencing. CHIP-associated mutations displayed a diverse distribution pattern through the HRS cell and microenvironmental tissue components, with significant representation in both (case 5, Fig. 1C), in only the microenvironment (case 2, Fig. 1A; case 1, Fig. 2D), or in none of them (case 4, Fig. 1B; and also case 3 with little spreading in reactive tissue cells, Supplementary Fig. S2). Notably, in the three patients with significant tissue involvement by clonal hematopoiesis, who all failed first-line chemotherapy, a large part of the
Figure 2. Trajectories of clonal hematopoiesis in a patient sequentially developing cHL and AML (case 1). A–C, Nodular sclerosis cHL lymph node biopsy immunostained (red labeling) for CD30 shows various HRS cells strongly expressing this cHL diagnostic marker (A). Immunostaining for the B cell–specific transcription factor PAX5 (B) shows nuclear positivity in a multinucleated Reed–Sternberg cell (black arrow) and, to a higher intensity, in sparse bystander B cells (one indicated by the red arrow). In C, CD3 immunostaining highlights the abundant reactive T cells in the microenvironment surrounding HRS cells. D, Spreading of the DNMT3A R882H mutation: (i) through preneoplastic hematopoiesis in the bone marrow and blood, with multilineage myeloid cell, B-cell, and T-cell involvement and then (ii) through the neoplastic tissues of AML and cHL, in the latter involving reactive tissue cells (mostly T cells) but not HRS cells. Also indicated are the genetic lesions leading to the development of the AML clone (NPM1 mutation) and the HRS cell clone (STAT6 and SOCS1 mutations), arising, respectively, from a myeloid progenitor belonging to clonal hematopoiesis and a mature B cell not belonging to clonal hematopoiesis. HSC, hematopoietic stem cell.
reactive microenvironment (mostly lymphoid and confirmed to be polyclonal upon T-cell receptor gene rearrangement analysis) belonged to HSPC-derived clonal hematopoiesis (33%–92% of cells based on VAF). Considering that both the HRS cell clone and the microenvironment supporting its growth (13) are central features of cHL pathogenesis, and that chemotherapy does not clear clonal hematopoiesis (9), clonal hematopoiesis spreading in the cHL tissue and all not progressing after first-line therapy. COPP/ABV stands for cyclophosphamide, vincristine sulfate, prednisone, procarbazine hydrochloride/doxorubicin hydrochloride, bleomycin, vinlblastine sulfate.

Another interesting finding reported here (case 5) is the first description of mutations in the epigenetic DNA modifiers DNMT3A and TET2 in tumor cells of cHL (see also Supplementary Discussion). While relatively frequent in tumor cells of cHL (and non-Hodgkin) B-cell lymphomas (33%–92% of cells based on VAF). Considering that both the HRS cell clone and the microenvironment supporting its growth (13) are central features of cHL pathogenesis, and that chemotherapy does not clear clonal hematopoiesis (9), clonal hematopoiesis spreading in the cHL tissue components might contribute to the development of this lymphoma and influence its prognosis. However, this hypothesis should be ascertained in larger patient cohorts.

Regarding the TET2 disruptive variant observed in the lymphoid microenvironment of case 5, we note that, although Buscarlet and colleagues showed an exclusion of TET2-inactivating mutations from the mature T-cell compartment in healthy individuals with CHIP (25), in case 5 the TET2 variant was presumably subclonal to (i.e., occurred later than) the DNMT3A mutation concomitantly present in the microenvironment (because the VAFs of these two mutations in whole lymph node sections were, respectively, 22% and 32% in the onset sample, and 38% and 27% in the relapse sample). This latter finding is in keeping with the multipotent involvement (T-cell lineage included) typical of mutant DNMT3A that was also shown by Buscarlet and colleagues (25) and may point to mutant DNMT3A being permissive to propagation of a subsequent TET2 disruptive variant through the T-cell lineage. However, we also note that, in the microdissected tumor microenvironment of case 5, TET2 mutation VAF was not particularly high (8.4%), and hence we cannot formally exclude that it was entirely contributed by non-T cells.

We also show that the tumor clones of multiple lymphoid and myeloid neoplasms developing in the same patient with

---

**Table 2. Clinicopathologic features of cHL cases stratified by clonal hematopoiesis distribution in the tissue**

<table>
<thead>
<tr>
<th>N = 40 patients</th>
<th>Clonal hematopoiesis in cHL tissue</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>Extensive* (n = 3)</td>
<td>Absent/nonextensive (n = 37)</td>
</tr>
<tr>
<td>&gt;60 years</td>
<td>1 (33%)</td>
<td>9 (24%)</td>
</tr>
<tr>
<td>&lt;60 years</td>
<td>2 (67%)</td>
<td>28 (76%)</td>
</tr>
<tr>
<td>EBV status</td>
<td>EBV+</td>
<td>EBV-</td>
</tr>
<tr>
<td>EBV+</td>
<td>1 (33%)</td>
<td>8 (22%)</td>
</tr>
<tr>
<td>EBV-</td>
<td>2 (67%)</td>
<td>29 (78%)</td>
</tr>
<tr>
<td>Histotype</td>
<td>Nodular sclerosis</td>
<td>Mixed cellularity</td>
</tr>
<tr>
<td>Nodular sclerosis</td>
<td>1 (33%)</td>
<td>21 (57%)</td>
</tr>
<tr>
<td>Mixed cellularity</td>
<td>2 (67%)</td>
<td>12 (32%)</td>
</tr>
<tr>
<td>Other</td>
<td>0 (0%)</td>
<td>4 (11%)</td>
</tr>
<tr>
<td>Clinical stage</td>
<td>Early (≤ IIA)</td>
<td>Advanced (≥ IIB)</td>
</tr>
<tr>
<td>Early (≤ IIA)</td>
<td>1 (33%)</td>
<td>13 (37%)&lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
<tr>
<td>Advanced (≥ IIB)</td>
<td>2 (67%)</td>
<td>22 (63%)&lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
<tr>
<td>Outcome of first-line therapy&lt;sup&gt;a&lt;/sup&gt;</td>
<td>No progression</td>
<td>Progression</td>
</tr>
<tr>
<td>No progression</td>
<td>0 (0%)</td>
<td>24 (69%)&lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
<tr>
<td>Progression</td>
<td>3 (100%)</td>
<td>11 (31%)&lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
<tr>
<td>Follow-up in months&lt;sup&gt;a&lt;/sup&gt;</td>
<td>0–6–35</td>
<td>64 (median)&lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>0–149 (range)&lt;sup&gt;c&lt;/sup&gt;</td>
<td></td>
</tr>
</tbody>
</table>

*Extensive: VAF ≥10%.

<sup>a</sup>By Fisher exact test except for comparison of follow-up where t test was used.

<sup>b</sup>Nodular sclerosis versus all other subtypes.

<sup>c</sup>Clinical stage at diagnosis was not available for two patients (UPN26 and UPN40).

<sup>d</sup>ABVD in all cases, with the following exceptions of little relevance: (i) COPP/ABV in pediatric patient UPN27, not showing clonal hematopoiesis and not progressing after first-line therapy; (ii) COPP without vincristine in elderly patient UPN41/case 3, whose outcome was not evaluable; and (iii) omission of bleomycin in 3/35 patients (UPN13, UPN25/case 4, and UPN30, all without extensive clonal hematopoiesis and not progressing after first-line therapy). COPP/ABV stands for cyclophosphamide, vincristine sulfate, prednisone, procarbazine hydrochloride/doxorubicin hydrochloride, bleomycin, vinlblastine sulfate.

<sup>e</sup>Outcome was not available for one patient (UPN40) and not evaluable in another patient (UPN41/case 3) who died early due to acute chemotherapy toxicity.

<sup>f</sup>Follow-up was not available for one patient (UPN40) and not evaluable in another (UPN41/case 3).
Clonal hematopoiesis do not necessarily derive all from clonal hematopoiesis, even when (as in case 1 here) the specific mutations driving clonal hematopoiesis in that patient can be present in the tumor clone of the cancer histologies in question and even when such mutations extensively spread through the cell-of-origin lineages and the microenvironment of the neoplasms affecting that patient. Thus, clonal hematopoiesis trajectories must be carefully disentangled to correctly interpret the histogenesis and pathogenesis of multiple blood cancers arising in patients with clonal hematopoiesis.

Finally, the observations made on case 1 raise the question as to whether his AML was related or not to the previous therapy for cHL (see also Supplementary Discussion). The AML clone lacked the genetic signature of typical therapy-related cases (i.e., TPS3 or PPMID mutations; complex karyotype and/or loss of chromosomes 5 or 7; refs. 1, 5, 8, 26) and instead carried an NPM1 mutation with normal karyotype, typical of de novo AML (20). These findings may suggest a derivation of the leukemia from a large, and thus high-risk, preexisting CHIP clone (driven by mutant DNMT3A), similar to another recently described lymphoma patient with massive CHIP (sustained by mutant TET2 and ASXL1) who then developed NPM1-mutated AML (11). Further studies are needed to clarify the pathogenesis of such atypical posttherapy AML cases arising from CHIP in patients with lymphoma.

In conclusion, our data demonstrated that clonal hematopoiesis can spread through the neoplastic and/or nonneoplastic tissue components of cHL, with potential implications for the biology and clinical course of this mature B-cell malignancy.

METHODS

Patients' Samples

We analyzed various types of biological samples that were taken from case 1, as well as lymph node biopsies that were taken from five additional newly processed cHL cases, after the signature of a written informed consent form approved by our hospital review board and in accordance with the Declaration of Helsinki. Lymph node and bone marrow biopsies were fixed in formalin and B5, respectively, and routinely processed according to standard immunohistologic procedures; a portion of the lymph node biopsy was in parallel frozen for laser microdissection (see next paragraph). B cells and T cells of case 1 were purified (to a level ≥98%) from peripheral blood by MACS technology using anti-CD19 and anti-CD3 microbeads (Miltenyi Biotec), respectively, and MS columns following manufacturer recommendations. Genomic DNA was extracted from bone marrow aspirate and peripheral blood samples of case 1 using QIAamp DNA Blood Midi Kit (QIAGEN), and from his purified B and T cells using AllPrep DNA/RNA Mini Kit (QIAGEN). The Gentra Puregene kit (QIAGEN) was instead used to extract DNA from whole biopsy sections of case 5 (formalin-fixed paraffin-embedded at onset; frozen at relapse), case 1 (frozen at onset) and case 2 (frozen at relapse) in order to validate their WES data obtained from microdissected sections with standard PCR, followed by fragment length analysis using the T-cell receptor gamma rearrangements Molecular Analysis Kits (Vitro Master Diagnostica).

Laser Microdissection

Laser microdissection of HRS and reactive cells from lymph node biopsy sections of the six newly processed cases was performed as described previously (15). Briefly, HRS cells were microdissected from frozen sections stained with hematoxylin and eosin using an Olympus microscope equipped with PALM Microlaser Technology. Eight-micron-thick sections were mounted on membrane-covered slides (Membrane Slide 1.0 PEN, Zeiss) and air-dried at room temperature overnight. Sections were then fixed for 10 minutes in acetone, air-dried at room temperature for 5 minutes, incubated with hematoxylin (Dako-Agilent) for 2 minutes, washed in molecular biology-grade water for 2 minutes, incubated with 2% eosin for 1 minute, washed again, and air-dried overnight at room temperature. A total of approximately 1,450 HRS cells were microdissected as single cells (or, less frequently, as small aggregates of 2–4 cells attached to one another) according to their characteristic cytomorphology and large cell size, and then catapulted into an opaque adhesive cap of a 0.5 mL tube (Zeiss) in groups of 200 to 300 cells per cap. A similar number of non-HRS cells mostly of lymphoid morphology and T-cell immunophenotype (representative example in Fig. 2C; Supplementary Fig. S1) were microdissected from the same sections in areas of 200 to 300 cells and collected in separate caps (some contamination by macrophages, eosinophils, and/or other cell types cannot be excluded, but it would likely have limited relevance, especially in cases showing extensive clonal hematopoiesis with VAF ≥10%). Following DNA extraction using the Gentra Puregene protocol (QIAGEN), whole-genome amplification (WGA) was performed in duplicate from both the HRS and the reactive cell sample as described previously (15).

Targeted Sequencing of Patient Samples

All DNA samples from the six newly processed cases were subjected to molecularly barcoded targeted sequencing of 43 genes recurrently mutated in myeloid neoplasms (QIAseq Targeted DNA Custom Panel–CDHS-136402-1040-Qiagen; Supplementary Table S1A), using 40 to 80 ng of input DNA. In addition, the microdissected HRS and reactive cell WGA DNA (250 ng) of case 1 was subjected to molecularly barcoded targeted sequencing of six JAK–STAT pathway genes recurrently mutated in cHL (QIAseq Targeted DNA Custom Panel–CDHS-16895Z-163-Qiagen; Supplementary Table S1B). Libraries were generated according to the manufacturer’s instructions and sequenced on an Illumina MiSeq instrument for 2 × 151 cycles, using MiSeq Reagent Kit v2 or v3. The mean unique depth of coverage was 2.856× for the myeloid gene panel and 1.716× for the JAK–STAT pathway gene panel.

Bioinformatics Analysis of Targeted Sequencing Data

Bioinformatics mapping and variant calling of targeted sequencing data [European Nucleotide Archive (ENA) accession number PRJEB42867] was performed with QIAGEN smCounter algorithm v1 or v2 with default settings (27), and variant annotation was performed with Illumina Variant Studio 3.0. Sequencing variants were then subjected to the further following filters and retained only if: (i) variants were predicted to change the gene coding sequence or involved the conserved splice-site (i.e., the four nucleotides surrounding the exon–intron junction); (ii) variants were not present in the Exome Aggregation Consortium (ExAC) database of normal individuals with a population frequency ≥1% (as provided by Illumina Variant Studio 3.0); (iii) variants were present at an allele frequency ≥2%; and (iv) indels were not located in homopolymeric stretches of five nucleotides or longer. In addition, variants called in HRS and reactive lymphoid cell WGA DNA had to be called in both WGA replicates and their mean weighted VAF (reported in Table 1) had to be ≥2%. The SOCS3 disruptive mutation P83afsX25 (a frameshift deletion of 26 nucleotides) was called in only one of the WGA HRS cell duplicates (VAF 98.6%; 72 unique supporting reads) due to poor coverage of this guanine-cytosine-rich gene in the other duplicate; in the latter, however, visual inspection of the BAM file showed...
21/25 mutant raw reads, and the deletion was confirmed by standard Sanger sequencing of the same WGA DNA (cycling conditions and primers available upon request).

**WES Analysis of Clonal Hematopoiesis in a Previous cHL Patient Cohort**

We also analyzed our WES data from non-HRS cells of 34 cHL cases that we previously used as a matched counterpart to call somatic mutations in HRS cells of this malignancy (ref. 15; ENA accession number PRJEB25980). DNA from microdissected HRS and reactive cells had been subjected to duplicate WGA and independent WES of the duplicates (referred to as T1-T2 and N1-N2, respectively); furthermore, in most cases (26/34) unamplified genomic DNA from whole-blood leukocytes was also subjected to WES (15). Mean unique coverage was 157× for the 26 blood leukocyte samples and 149× for the 8 microdissected reactive sample pairs. Bioinformatics analysis focused on a target region of interest represented by 35 genes associated with age-related clonal hematopoiesis as defined by Tuval and Shluss (ref. 9 and Table 1 therein), whose genomic coordinates were retrieved from the NCBI Reference Sequence Database on human genome GRCh37.

**Bioinformatics Reanalysis of WES Data**

For each sample subjected to WES, the .mpileup file was generated by means of the SAMtools v.1.4 command mpileup with default parameters except disabling the base alignment quality computation as recommended (28) for the subsequent Varscan2 variant calling; see further below) and increasing the minimum mapping quality from 0 to 1 while allowing a maximum depth of 1 billion (instead of 8,000) reads. We then called single-nucleotide variants and indels separately for each sample through Varscan2 (version 2.4.3) command mpileup2snp and mpileup2indel, respectively, using default settings (except that the minimum coverage depth to make a call was increased from 8 to 10, and the P-value threshold was changed from 0.99 to 0.05). Variant mean unique reads obtained by the bam-read count utility of Varscan2 with default parameters (except raising the minimum base quality from 0 to 20 in all supporting reads). Variants had then to pass Varscan2 fpfilter with default setting (except the minimum number of variant-supporting reads was changed from 4 to 2, and the minimum variant allele frequency was changed from 5% to 1%); we also retained variants with supporting reads that were nevertheless flagged as “NoReadCounts” by the fpfilter (this is a known bug of Varscan2). Moreover, regarding WGA samples, variants had to be called in both duplicates to efficiently control for false positives potentially introduced by the WGA step as described previously (15). Annotation of the variants was performed by both SNPEff (version n. 41/c) and wAnnoVar (29), referring to the following database versions: 1000G: 2015 aug; ExAC: excl03; dbSNP: avinson147; cosmic: cosmics1; clinvar: 20170501; and gnomAD: gnomAD_exome and gnomAD_genome (v.2). We then excluded variants with a gnomAD_genome frequency in normal individuals higher than 40%, and focused on sequence variants in coding exons or conserved splice sites. These variants were finally subjected to the following further filters and retained only if: (i) indels were not located in homopolymeric stretches of five nucleotides or longer; (ii) variants were present at an allele frequency of at least 2%; (iii) variants fulfilled the definition of a likely driver event according to functional experimental evidence (for the CBL(207A) variant, ref. 19, in case 2) or according to Abelson and colleagues (7); and (iv) variants were validated by molecularly barcoded targeted sequencing at high depth (mean unique coverage of 4,175×) following the same experimental and bioinformatics pipeline described in a previous section (“Bioinformatics analysis of targeted sequencing data”) except that for case 2, validation was performed on whole-section DNA and that for the microdissected HRS and reactive cell samples of cases 4 and 5, we pooled the WGA DNA of the two replicates before library generation.

**Authors’ Disclosures**

M.P. Martelli reports personal fees from AbbVie, Amgen, Pfizer, Jazz Pharmaceuticals, Novartis, and Janssen outside the submitted work. No disclosures were reported by the other authors.

**Authors’ Contributions**

A. Venanzi: Conceptualization, data curation, formal analysis, methodology, writing–original draft, writing–review and editing.

A. Marra: Conceptualization, data curation, formal analysis, methodology, writing–original draft, writing–review and editing.

G. Schiavoni: Data curation, formal analysis, funding acquisition, methodology.


P. Sportoleti: Methodology. S. Ascani: Histopathologic examinations of patients’ specimens. B. Falini: Funding acquisition, writing–review and editing.

E. Tiacci: Study direction, conceptualization, data curation, formal analysis, supervision, funding acquisition, writing–original draft, writing–review and editing.

**Acknowledgments**

This work was supported by a grant on cHL to E. Tiacci from AIRC (IG 2019, ID. 23732), a grant on AML to B. Falini from AIRC (IG 2019 number 23604), a grant on AML to B. Falini from ERC (Advanced Grant 2016 number 740230), the Leopold Grifﬁel prize from ARC (15) to A. Venanzi, and a grant on cHL to G. Schiavoni from the Department of Medicine, University of Perugia (Ricerca di Base 2017–2019).

Received November 10, 2020; revised January 14, 2021; accepted March 2, 2021; published ﬁrst April 10, 2021.

**References**


